Cargando…

Synpolydactyly and HOXD13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences

BACKGROUND: Type II syndactyly or synpolydactyly (SPD) is clinically very heterogeneous, and genetically three distinct SPD conditions are known and have been designated as SPD1, SPD2 and SPD3, respectively. SPD1 type is associated with expansion mutations in HOXD13, resulting in an addition of ≥ 7...

Descripción completa

Detalles Bibliográficos
Autores principales: Malik, Sajid, Girisha, KM, Wajid, Muhammad, Roy, Akhilesh K, Phadke, Shubha R, Haque, Sayedul, Ahmad, Wasim, Koch, Manuela C, Grzeschik, Karl-Heinz
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222244/
https://www.ncbi.nlm.nih.gov/pubmed/18072967
http://dx.doi.org/10.1186/1471-2350-8-78
_version_ 1782149345978613760
author Malik, Sajid
Girisha, KM
Wajid, Muhammad
Roy, Akhilesh K
Phadke, Shubha R
Haque, Sayedul
Ahmad, Wasim
Koch, Manuela C
Grzeschik, Karl-Heinz
author_facet Malik, Sajid
Girisha, KM
Wajid, Muhammad
Roy, Akhilesh K
Phadke, Shubha R
Haque, Sayedul
Ahmad, Wasim
Koch, Manuela C
Grzeschik, Karl-Heinz
author_sort Malik, Sajid
collection PubMed
description BACKGROUND: Type II syndactyly or synpolydactyly (SPD) is clinically very heterogeneous, and genetically three distinct SPD conditions are known and have been designated as SPD1, SPD2 and SPD3, respectively. SPD1 type is associated with expansion mutations in HOXD13, resulting in an addition of ≥ 7 alanine residues to the polyalanine repeat. It has been suggested that expansions ≤ 6 alanine residues go without medical attention, as no such expansion has ever been reported with the SPD1 phenotype. METHODS: We describe a large Pakistani and an Indian family with SPD. We perform detailed clinical and molecular analyses to identify the genetic basis of this malformation. RESULTS: We have identified four distinct clinical categories for the SPD1 phenotype observed in the affected subjects in both families. Next, we show that a milder foot phenotype, previously described as a separate entity, is in fact a part of the SPD1 phenotypic spectrum. Then, we demonstrate that the phenotype in both families segregates with an identical expansion mutation of 21 bp in HOXD13. Finally, we show that the HOXD13 polyalanine repeat is polymorphic, and the expansion of 2 alanine residues, evident in unaffected subjects of both families, is without clinical consequences. CONCLUSION: It is the first molecular evidence supporting the hypothesis that expansion of ≤ 6 alanine residues in the HOXD13 polyalanine repeat is not associated with the SPD1 phenotype.
format Text
id pubmed-2222244
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22222442008-02-01 Synpolydactyly and HOXD13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences Malik, Sajid Girisha, KM Wajid, Muhammad Roy, Akhilesh K Phadke, Shubha R Haque, Sayedul Ahmad, Wasim Koch, Manuela C Grzeschik, Karl-Heinz BMC Med Genet Research Article BACKGROUND: Type II syndactyly or synpolydactyly (SPD) is clinically very heterogeneous, and genetically three distinct SPD conditions are known and have been designated as SPD1, SPD2 and SPD3, respectively. SPD1 type is associated with expansion mutations in HOXD13, resulting in an addition of ≥ 7 alanine residues to the polyalanine repeat. It has been suggested that expansions ≤ 6 alanine residues go without medical attention, as no such expansion has ever been reported with the SPD1 phenotype. METHODS: We describe a large Pakistani and an Indian family with SPD. We perform detailed clinical and molecular analyses to identify the genetic basis of this malformation. RESULTS: We have identified four distinct clinical categories for the SPD1 phenotype observed in the affected subjects in both families. Next, we show that a milder foot phenotype, previously described as a separate entity, is in fact a part of the SPD1 phenotypic spectrum. Then, we demonstrate that the phenotype in both families segregates with an identical expansion mutation of 21 bp in HOXD13. Finally, we show that the HOXD13 polyalanine repeat is polymorphic, and the expansion of 2 alanine residues, evident in unaffected subjects of both families, is without clinical consequences. CONCLUSION: It is the first molecular evidence supporting the hypothesis that expansion of ≤ 6 alanine residues in the HOXD13 polyalanine repeat is not associated with the SPD1 phenotype. BioMed Central 2007-12-11 /pmc/articles/PMC2222244/ /pubmed/18072967 http://dx.doi.org/10.1186/1471-2350-8-78 Text en Copyright © 2007 Malik et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Malik, Sajid
Girisha, KM
Wajid, Muhammad
Roy, Akhilesh K
Phadke, Shubha R
Haque, Sayedul
Ahmad, Wasim
Koch, Manuela C
Grzeschik, Karl-Heinz
Synpolydactyly and HOXD13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences
title Synpolydactyly and HOXD13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences
title_full Synpolydactyly and HOXD13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences
title_fullStr Synpolydactyly and HOXD13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences
title_full_unstemmed Synpolydactyly and HOXD13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences
title_short Synpolydactyly and HOXD13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences
title_sort synpolydactyly and hoxd13 polyalanine repeat: addition of 2 alanine residues is without clinical consequences
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222244/
https://www.ncbi.nlm.nih.gov/pubmed/18072967
http://dx.doi.org/10.1186/1471-2350-8-78
work_keys_str_mv AT maliksajid synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences
AT girishakm synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences
AT wajidmuhammad synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences
AT royakhileshk synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences
AT phadkeshubhar synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences
AT haquesayedul synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences
AT ahmadwasim synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences
AT kochmanuelac synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences
AT grzeschikkarlheinz synpolydactylyandhoxd13polyalaninerepeatadditionof2alanineresiduesiswithoutclinicalconsequences